Immunohistochemical studies with basal cytokeratin IHC for the basal breast cancer phenotype classification have almost exclusively addressed the fact that basal-phenotype tumors have poor prognosis, but they have also made the comparison in cohorts not selected by matching ER status (ER-negative) [10,11,16,17,20,23-25]. This evidence concerns the gene ESR1 and breast cancer.